Patents Assigned to Ed. Geistlich Soehne AG fuer Chemische Industrie
-
Patent number: 9034315Abstract: A multi-layer sheet of collagen membrane material includes a barrier layer including an outer smooth barrier face and further including a fibrous face opposite the smooth barrier face, and a matrix layer of collagen material adhered to the fibrous face, the matrix layer including collagen I, collagen III, or a combination thereof, the matrix layer carrying cultivated bone-forming cells including osteocytes, osteoblasts, stromal cells and/or stem cells committed to differentiation into bone-forming osteoblasts.Type: GrantFiled: August 25, 2006Date of Patent: May 19, 2015Assignee: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIEInventor: Peter Geistlich
-
Patent number: 9012444Abstract: Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.Type: GrantFiled: March 21, 2011Date of Patent: April 21, 2015Assignee: Ed. Geistlich Soehne AG fuer Chemische IndustrieInventors: H. Paul Redmond, Rolf W. Pfirrmann
-
Patent number: 8394397Abstract: A method of treatment for preventing or inhibiting growth of cancer cells utilizes an antineoplastic composition including an antineoplastic-effective amount of a methylol transfer agent (MTA) in combination with biodegradable adhesive capable of adhering to tissue of a living subject.Type: GrantFiled: March 26, 2004Date of Patent: March 12, 2013Assignee: Ed. Geistlich Soehne AG fuer Chemische IndustrieInventors: Ruediger Stendel, Rolf W. Pfirrmann
-
Patent number: 8354119Abstract: A resorbable extracelluar matrix for reconstruction of cartilage tissue includes a mixture of collagen I and collagen II in a respective ratio of from about 1:19 to 19:1. The matrix can be utilized as a scaffold implant for vertebral or meniscal cartilage regeneration.Type: GrantFiled: November 19, 2002Date of Patent: January 15, 2013Assignee: ED. Geistlich Soehne AG Fuer Chemische IndustrieInventors: Peter Geistlich, Lothar Schloesser
-
Patent number: 8304390Abstract: A method of treatment for preventing or reducing tumor growth in liver of a patient includes administering to the patient an effective about of taurolidine, taurultam or a mixture thereof, so as to prevent or reduce the tumor growth in the patient.Type: GrantFiled: February 9, 2006Date of Patent: November 6, 2012Assignee: Ed. Geistlich Soehne AG fuer Chemische IndustrieInventor: Rolf W. Pfirrmann
-
Patent number: 8293225Abstract: An implant for repair of a cartilaginous defect in a subject includes a collagen matrix charged with synovial cells. A method preparing an implant for repair of a cartilaginous defect in a subject includes obtaining a fluid containing synovial cells and charging the synovial cells to the matrix. A device for preparing a cell-charged implant includes a first chamber and a second chamber, the first and second chambers being separated by a membrane and a perforated filter. The membrane is adapted to collect cells from a cell-containing fluid introduced into the first chamber and the perforated filter is adapted to permit passage or diffusion of the fluid through the second chamber. A method for preparing a cell-charged implant utilizes the device.Type: GrantFiled: October 23, 2006Date of Patent: October 23, 2012Assignee: Ed. Geistlich Soehne AG Fuer Chemische IndustrieInventors: Birgit Schaefer, Lothar Schloesser
-
Patent number: 8236794Abstract: A method of treating mesothelioma in a mammal, whereby a methylol-containing compound is administered to the mammal intrapleurally.Type: GrantFiled: September 28, 2004Date of Patent: August 7, 2012Assignee: Ed. Geistlich Soehne AG fuer Chemische IndustrieInventor: Rolf W. Pfirrmann
-
Patent number: 8202860Abstract: Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and/or Taurultam and/or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantion methods and angiographic methods.Type: GrantFiled: October 29, 2009Date of Patent: June 19, 2012Assignee: Ed. Geistlich Soehne AG fuer Chemische IndustrieInventors: Ruediger Stendel, Rolf W. Pfirrmann
-
Patent number: 8084428Abstract: A method of repairing a meniscal tear of a subject includes providing a sheet of collagen membrane material having on one side thereof a smooth barrier face which inhibits cell adhesion thereon and inhibits passage of cells therethrough. The sheet has a fibrous face opposite the smooth barrier face, the fibrous face allowing cell growth thereon. The collagen is predominantly collagen I. The sheet of collagen membrane material is fixed over a meniscal tear so that the fibrous face is oriented toward the meniscal tear.Type: GrantFiled: September 1, 2006Date of Patent: December 27, 2011Assignee: Ed. Geistlich Soehne AG fuer Chemische IndustrieInventors: Myron Spector, Peter Geistlich, Lothar Schloesser, Roland Jakob, Jean-Francois Clemence
-
Patent number: 8030301Abstract: A method of inhibiting growth of a tumor cell in a mammal may include steps of administering to the mammal a first solution including a tumor-inhibiting methylol-containing compound, the first solution further including a first combination having a plurality of physiologically acceptable electrolytes or a second combination having at least one amino acid in combination with at least one physiologically acceptable electrolyte. Alternatively, another solution may be administered to the mammal containing a tumor-inhibiting methylol-containing compound, while concurrently administering to the mammal a further solution including the first combination with the plurality of physiologically acceptable electrolytes or the second combination with at least one said amino acid in combination with at least one physiologically acceptable electrolyte.Type: GrantFiled: December 22, 2005Date of Patent: October 4, 2011Assignee: Ed. Geistlich Soehne AG Fuer Chemische IndustrieInventor: Rolf W. Pfirrmann
-
Publication number: 20110172213Abstract: Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.Type: ApplicationFiled: March 21, 2011Publication date: July 14, 2011Applicant: Ed. Geistlich Soehne AG fuer chemische IndustrieInventors: H. Paul Redmond, Rolf W. Pfirrmann
-
Patent number: 7928102Abstract: A composition formed by subjecting to ionizing radiation a combination containing a radiation-protective amount of PVP along with a solution, gel or adhesive including taurolidine, taurultam or a mixture thereof; or an aggregate including collagen-free crystals of taurolidine, taurultam or a mixture thereof.Type: GrantFiled: January 4, 2007Date of Patent: April 19, 2011Assignee: Ed. Geistlich Soehne AG fuer Chemische IndustrieInventors: Paul H. Redmond, Rolf W. Pfirrmann
-
Patent number: 7914817Abstract: Patients suffering from inflammatory bowel disease such as Crohn's disease or ulcerative colitis are treated either orally or intravenously with methylol transfer agents, such as taurolidine and/or taurultam. These agents can be used in combination with other drugs thereby allowing the use of smaller amounts of the other drugs and limiting unwanted side effects.Type: GrantFiled: January 24, 2005Date of Patent: March 29, 2011Assignee: Ed. Geistlich Soehne AG fuer Chemische IndustrieInventors: H. Paul Redmond, Rolf W. Pfirrmann
-
Patent number: 7910580Abstract: Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.Type: GrantFiled: January 18, 2008Date of Patent: March 22, 2011Assignee: Ed. Geistlich Soehne AG Fuer Chemische IndustrieInventors: H. Paul Redmond, Rolf W. Pfirrmann
-
Patent number: 7892530Abstract: Tumor metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of Interleukin-2 and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.Type: GrantFiled: September 25, 2006Date of Patent: February 22, 2011Assignee: ED. Geistlich Soehne AG Fuer Chemische IndustrieInventors: H. Paul Redmond, Rolf W. Pfirrmann
-
Publication number: 20100291173Abstract: A method of improving renal function in a mammal suffering from, or at risk of developing, at least partial renal failure or renal dysfunction, includes administering to renal tissue of the mammal, a combination comprising a non-viral vector comprising a non-viral particulate carrier which carries a therapeutically effective amount of genetic material capable of expressing a renal function-enhancing Osteogenic Protein-1/Bone Morphogenic Protein-7 (OP-1/BMP-7) polypeptide in the renal tissue.Type: ApplicationFiled: September 4, 2007Publication date: November 18, 2010Applicant: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIEInventors: Myron Spector, Peter Geistlich
-
Publication number: 20100081649Abstract: A method of inhibiting growth of a tumor cell in a mammal may include steps of administering to the mammal a first solution including a tumor-inhibiting methylol-containing compound, the first solution further including a first combination having a plurality of physiologically acceptable electrolytes or a second combination having at least one amino acid in combination with at least one physiologically acceptable electrolyte. Alternatively, another solution may be administered to the mammal containing a tumor-inhibiting methylol-containing compound, while concurrently administering to the mammal a further solution including the first combination with the plurality of physiologically acceptable electrolytes or the second combination with at least one said amino acid in combination with at least one physiologically acceptable electrolyte.Type: ApplicationFiled: December 22, 2005Publication date: April 1, 2010Applicant: Ed. Geistlich Soehne AG fuer chemische IndustrieInventor: Rolf Pfirrmann
-
Publication number: 20100040667Abstract: A method of treatment for treating, at least partially preventing, inhibiting or reducing growth of a bone tumor in a subject, including at least partially removing a bone tumor from a subject and contacting an area of bone adjacent to where the tumor was at least partially removed with a gel containing a tumor growth-inhibiting methylol transfer agent.Type: ApplicationFiled: September 6, 2007Publication date: February 18, 2010Applicant: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIEInventor: Rolf W. Pfirrmann
-
Publication number: 20090186062Abstract: A method of repairing a meniscal tear of a subject includes providing a sheet of collagen membrane material having on one side thereof a smooth barrier face which inhibits cell adhesion thereon and inhibits passage of cells therethrough. The sheet has a fibrous face opposite the smooth barrier face, the fibrous face allowing cell growth thereon. The collagen is predominantly collagen I. The sheet of collagen membrane material is fixed over a meniscal tear so that the fibrous face is oriented toward the meniscal tear.Type: ApplicationFiled: September 1, 2006Publication date: July 23, 2009Applicant: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIEInventors: Myron Spector, Peter Geistlich, Lothar Schloesser, Roland Jakob, Jean-Francois Clemence
-
Publication number: 20090156584Abstract: A composition formed by subjecting to ionizing radiation a combination containing a radiation-protective amount of PVP along with a solution, gel or adhesive including taurolidine, taurultam or a mixture thereof; or an aggregate including collagen-free crystals of taurolidine, taurultam or a mixture thereof.Type: ApplicationFiled: January 4, 2007Publication date: June 18, 2009Applicant: ED. GEISTLICH SOEHNE AG FUER CHEMISCHE INDUSTRIEInventors: Paul H. Redmond, Rolf W. Pfirrmann